Inside information: Orion upgrades full-year outlook for 2024
11 Septiembre 2024 - 1:30AM
UK Regulatory
Inside information: Orion upgrades full-year outlook for 2024
ORION CORPORATION
STOCK EXCHANGE RELEASE – INSIDE INFORMATION
11 SEPTEMBER 2024 at 09:30 EEST
Inside information: Orion upgrades full-year outlook for
2024
Orion Corporation upgrades the full-year outlook for 2024 both
for the part regarding net sales and operating profit. Orion’s
product sales and royalty income has continued to grow faster than
expected during the second half of 2024 and this good development
is anticipated to continue during the remainder of the year. Due to
these reasons, Orion upgrades the full-year outlook for 2024.
The outlook for 2024 includes one Nubeqa® sales-related
milestone payment of EUR 70 million which is included in both the
net sales outlook and the operating profit outlook. Orion expects
to record this milestone payment in Q3 2024.
New full-year outlook, provided on 11 September
2024
Net sales are estimated to be EUR 1,470 million to EUR 1,510
million.
Operating profit is estimated to be EUR 370 million to EUR 400
million.
Previous full-year outlook, provided on 1 July
2024
Net sales are estimated to be EUR 1,440 million to EUR 1,480
million.
Operating profit is estimated to be EUR 350 million to EUR 380
million.
Orion Corporation
Liisa Hurme
President and CEO |
|
Olli Huotari
SVP, Corporate Functions |
|
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a
builder of well-being for over a hundred years. We develop,
manufacture and market human and veterinary pharmaceuticals and
active pharmaceutical ingredients. Orion has an extensive portfolio
of proprietary and generic medicines and consumer health products.
The core therapy areas of our pharmaceutical R&D are oncology
and pain. Proprietary products developed by Orion are used to treat
cancer, neurological diseases and respiratory diseases, among
others. Orion's net sales in 2023 amounted to EUR 1,190 million and
the company had about 3,600 employees at the end of the year.
Orion's A and B shares are listed on Nasdaq Helsinki.
Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
